PACB Pacific Biosciences of California, Inc. - Common Stock
$1,23
السعر · أغسطس 19, 2026
البيانات الأساسية اعتبارًا من أغسطس 6, 2026
نطاق 52 أسبوعًا
$1–$3
10% of range
تقييم المحللين
BUY
14 analysts
السعر المستهدف
$2
+86% upside
P/E (TTM)
-0.7
ROE
-1634.9%
هامش صافي الربح
-341.5%
حول Pacific Biosciences of California, Inc. - Common Stock نظرة عامة على الشركة من ويكيبيديا
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
اقرأ المزيد
Pacific Biosciences of California, Inc. (a.k.a. PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
History
The company was founded based on research done at Cornell University that combined semiconductor processing and photonics with biotechnology research. Three graduate students in the lab of Professors Watt W. Webb — Jonas Korlach — and Harold Craighead — Steve Turner and Mathieu Foquet — became the first employees.
It began under the name Nanofluidics, Inc. The company raised nearly US$400,000,000 in six rounds of primarily venture capital financing, making it one of the most capitalized startups in 2010 leading up to their public offering in October of that year. Key investors included Mohr Davidow Ventures, Kleiner, Perkins, Caufield & Byers, Alloy Ventures, and Wellcome Trust.
The company's first commercial product, the PacBio RS, was sold to a limited set of customers in 2010 and was commercially released in early 2011. A subsequent version of the sequencer called the PacBio RS II was released in April 2013.
Leadership
In 2004, Kleiner Perkins entrepreneur-in-residence Hugh Martin became CEO. On 6 January 2012 board member Michael Hunkapiller, PhD assumed the role of CEO. Hunkapiller retired in September 2020, and was replaced by chairman of the board Christian Henry. Henry was a former executive VP and chief commercial officer of Illumina before joining the board at PacBio in July 2018.
Illumina: attempted acquisition
On 1 November 2018, Illumina, Inc. agreed to purchase PacBio for US$1.2 billion in cash. The deal was expected to close in the fourth quarter of 2019. In December 2019, the Federal Trade Commission sued to block the acquisition. The deal was abandoned with an announcement on 2 January 2020. Illumina further agreed to pay Pacific Biosciences a $98 million US termination fee plus previously agreed upon deal extension payments of $22 million US in February and $6 million US in March 2020.
Sequencing technology
Sequencing instruments
The company's first scientific instrument, called the PacBio RS, was released to a limited set of customers in late 2010., with full commercial release in early 2011. Sequencing provider GATC Biotech was selected by Pacific Biosciences as its first European service provider in late 2010. A new version of the sequencer was released in April 2013 it produced longer sequence reads and higher throughput than the original RS instrument. The RS instrument will officially be supported until the end of 2021. In September 2015, the company released a new sequencing instrument, the Sequel System, with increased sequencing capacity at a smaller size and lower price compared to the PacBio RS II. Subsequently, in October 2022, PacBio launched a new sequencing system, which can sequence 1,300 human genomes per year as compared to 86 per year of the previous PacBio sequencing machines.
Reagents and SMRT Cells
To use either instrument, customers must also purchase reagent packs for DNA preparation and sequencing and small consumables called "SMRT Cells." Cells for early forms of the sequencer are slightly less than one-centimeter square and contains tens of thousands of zero-mode waveguides, whereas newer systems have a higher density of cells and contain 25 million zero-mode waveguides (ZMWGs), allowing for faster DNA sequencing.
Software and applications
Their secondary analysis bioinformatics product for the RS, called “SMRT Analysis”, was open source. For the Sequel system the secondary analysis software was reorganized as the "SMRT Link" application. In 2013, the company released new bioinformatics tools for automated genome assembly (HGAP) and finishing (Quiver).
المصدر: ويكيبيديا (الإنجليزية), CC BY-SA 4.0 · عرض على ويكيبيديا ↗
PACB لقطة سريعة للسهم السعر، القيمة السوقية، مكرر الربحية (P/E)، ربحية السهم (EPS)، العائد على حقوق الملكية (ROE)، نسبة الدين إلى حقوق الملكية، نطاق 52 أسبوعًا
السعر
$1.23
القيمة السوقية
$382M
P/E (TTM)
-0.7
ربح السهم (آخر 12 شهرًا)
$-1.82
الإيرادات (آخر 12 شهرًا)
$160M
عائد التوزيعات
—
ROE
-1634.9%
D/E الدين/حقوق الملكية
—
نطاق 52 أسبوعًا
$1 – $3
PACB مخطط سعر السهم OHLCV يومي مع مؤشرات فنية — تحريك وتكبير وتخصيص عرضك
Configure
أداء 10 سنوات اتجاهات الإيرادات وصافي الدخل والهوامش وربحية السهم
الإيرادات وصافي الدخل
$160M
2016-12-31
→
2025-12-31
ربح السهم
$-1.82
2018-12-31
→
2025-12-31
التدفق النقدي الحر
$-114M
2016-12-31
→
2025-12-31
الهوامش
-341.5%
2016-12-31
→
2025-12-31
التقييم نسب مكرر الربحية (P/E)، مكرر المبيعات (P/S)، مكرر القيمة الدفترية (P/B)، EV/EBITDA — هل السهم مرتفع السعر أم رخيص؟
المقياس
اتجاه 5 سنوات
PACB
متوسط الأقران
P/E (TTM)
-0.7
17.5
P/S (TTM) (السعر / المبيعات (آخر 12 شهرًا))
2.4
3.3
P/B (السعر / القيمة الدفترية)
71.5
2.1
Price / FCF (السعر / التدفق النقدي الحر)
-3.4
—
الربحية هامش الربح الإجمالي والتشغيلي والصافي؛ العائد على حقوق الملكية (ROE)، العائد على الأصول (ROA)، العائد على رأس المال المستثمر (ROIC)
المقياس
اتجاه 5 سنوات
PACB
متوسط الأقران
Gross Margin (هامش الربح الإجمالي)
28.6%
42.5%
Operating Margin (هامش التشغيل)
-346.1%
—
Net Profit Margin (هامش صافي الربح)
-341.5%
-56.5%
ROA (العائد على الأصول)
-53.4%
-17.2%
ROE
-1634.9%
-41.3%
ROIC
-10360.5%
—
الصحة المالية الديون، السيولة، الملاءة المالية — قوة الميزانية العمومية
المقياس
اتجاه 5 سنوات
PACB
متوسط الأقران
Current Ratio (النسبة الحالية)
5.1
4.9
Quick Ratio (النسبة السريعة)
4.3
—
النمو نمو الإيرادات وربحية السهم وصافي الدخل: مقارنة بالعام السابق (YoY)، متوسط النمو السنوي المركب لـ 3 سنوات (3Y CAGR)، متوسط النمو السنوي المركب لـ 5 سنوات (5Y CAGR)
المقياس
اتجاه 5 سنوات
PACB
متوسط الأقران
Revenue YoY (الإيرادات مقارنة بالعام السابق)
3.9%
—
Revenue CAGR 3Y (معدل نمو الإيرادات السنوي المركب لـ 3 سنوات)
7.6%
—
Revenue CAGR 5Y (معدل نمو الإيرادات السنوي المركب لـ 5 سنوات)
15.2%
—
كفاءة رأس المال معدل دوران الأصول، معدل دوران المخزون، معدل دوران المستحقات
المقياس
اتجاه 5 سنوات
PACB
متوسط الأقران
PACB توافق الآراء التحليلي آراء المحللين الصعودية والهبوطية، السعر المستهدف لمدة 12 شهرًا، الصعود
شراء
14 محللين
- شراء قوي 4 28,6%
- شراء 5 35,7%
- احتفاظ 4 28,6%
- بيع 1 7,1%
- بيع قوي 0 0,0%
السعر المستهدف لمدة 12 شهرًا
6 محللين · 2026-08-14
الوسيط
$2.50
المتوسط
$2.29
← أقل من جميع الأهداف
$1.23
منخفض
$1.25
مرتفع
$3.00
السعر المستهدف الوسيط
$2.50
+103,0%
السعر المستهدف المتوسط
$2.29
+86,1%
سجل الأرباح ربحية السهم الفعلية مقابل التقديرات، نسبة المفاجأة %، معدل التجاوز، تاريخ الأرباح التالي
متوسط المفاجأة
-0.19%
| الفترة | EPS Actual | EPS المتوقع | المفاجأة |
|---|---|---|---|
| 30 يونيو، 2026 | $-0.14 | $-0.13 | -0.01% |
| 31 مارس، 2026 | $-0.12 | $-0.14 | 0.02% |
| 31 ديسمبر، 2025 | $-0.12 | $-0.15 | 0.03% |
| 30 سبتمبر، 2025 | $-0.13 | $-0.15 | 0.03% |
| 30 يونيو، 2025 | $-0.14 | $-0.17 | 0.03% |
| 31 مارس، 2025 | $-1.44 | $-0.19 | -1.2% |
مقارنة الأقران (الصناعة الفرعية GICS) المقاييس الرئيسية مقابل أقران القطاع
| الرمز | القيمة السوقية | P/E | الإيرادات سنويًا | هامش الربح الصافي | ROE | هامش الربح الإجمالي |
|---|---|---|---|---|---|---|
| PACB | $565M | -1.0 | 3.9% | -341.5% | -1634.9% | 28.6% |
| CYRX | $479M | 6.9 | 12.4% | 44.4% | 15.3% | 47.1% |
| MLAB | $489M | 73.1 | 3.4% | 2.7% | 3.7% | 63.5% |
| CTKB | $649M | 505.0 | 0.52% | -33.0% | -18.5% | 51.8% |
| OABI | — | — | — | — | — | — |
| DNA | $484M | -1.5 | -25.1% | -183.8% | -55.8% | — |
| TKNO | $204M | -11.9 | 7.3% | -42.6% | -23.8% | 33.2% |
| LAB | $495M | -6.4 | -6.2% | -87.8% | -17.6% | 49.9% |
| CDXS | $147M | -3.3 | 18.6% | -62.5% | -82.8% | — |
| LFCR | $249M | -5.3 | 0.47% | -30.0% | -461.3% | 31.3% |
| QSI | — | — | — | — | — | — |
الأساسيات الكاملة جميع المقاييس حسب السنة — قائمة الدخل، الميزانية العمومية، التدفق النقدي
قائمة الدخل 17
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Cost of Revenue | $114M | $117M | $148M | $79M | $72M | $46M | $56M | $54M | $59M | $47M | $39M | $37M | |
| Gross Profit | $46M | $37M | $53M | $49M | $59M | $33M | $35M | $25M | $35M | $44M | $53M | $23M | |
| R&D Expense | $97M | $135M | $187M | $193M | $113M | $64M | $60M | $63M | $65M | $68M | $60M | $48M | |
| SG&A Expense | $141M | $175M | $170M | $161M | $124M | $73M | $75M | $63M | $59M | $48M | $45M | $38M | |
| Operating Expenses | $600M | $512M | $387M | $356M | $269M | $137M | $135M | $126M | $124M | $115M | $83M | $86M | |
| Operating Income | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-101M | $-90M | $-71M | $-29M | $-63M | |
| Interest Expense | · | · | $14M | $15M | $13M | $267.0K | $3M | $2M | $3M | $3M | $3M | $3M | |
| Other Non-op | $15M | $24M | $33M | $8M | $93.0K | $2M | $1M | $848.0K | $516.0K | $103.0K | $364.0K | $-478.0K | |
| Pretax Income | $-546M | $-310M | $-318M | $-314M | $-275M | $29M | $-84M | · | · | · | · | · | |
| Income Tax | $318.0K | $316.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Net Income | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| EPS (Basic) | $-1.82 | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 | $-0.55 | $-0.76 | · | · | · | · | |
| EPS (Diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | · | · | · | · | |
| Shares (Basic) | 299,959,000 | 274,488,000 | 253,629,000 | 224,550,000 | 204,136,000 | 165,187,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| Shares (Diluted) | 299,959,000 | 288,366,000 | 253,629,000 | 224,550,000 | 204,136,000 | 174,970,000 | 152,527,000 | 135,094,000 | · | · | · | · | |
| EBITDA | $-554M | $-474M | $-334M | $-307M | $-210M | $-104M | $-101M | $-94M | $-81M | $-67M | $-25M | $-59M |
الميزانية العمومية 30
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $64M | $55M | $180M | $325M | $461M | $82M | $30M | $19M | $17M | $17M | $34M | $36M | |
| Short-term Investments | $216M | $335M | $452M | $447M | $584M | $237M | $19M | $84M | $46M | $55M | $49M | $65M | |
| Receivables | $35M | $28M | $37M | $19M | $24M | $17M | $15M | $9M | $13M | $11M | $5M | $3M | |
| Inventory | $49M | $59M | $57M | $50M | $25M | $14M | $13M | $18M | $23M | $16M | $11M | $11M | |
| Prepaid Expense | $11M | $19M | $17M | $10M | $7M | $5M | $3M | $3M | $2M | $10M | $12M | $2M | |
| Other Current Assets | · | · | · | · | · | · | · | · | $931.0K | $476.0K | $741.0K | $107.0K | |
| Current Assets | $375M | $496M | $742M | $852M | $1.10B | $356M | $81M | $132M | $102M | $109M | $111M | $118M | |
| PP&E (Net) | $24M | $31M | $36M | $42M | $33M | $25M | $30M | $34M | $38M | $15M | $9M | $7M | |
| PP&E (Gross) | $117M | $112M | $111M | $107M | $89M | $75M | $74M | $71M | $70M | $52M | $42M | $37M | |
| Accum. Depreciation | $92M | $82M | $75M | $65M | $56M | $50M | $44M | $37M | $32M | $37M | $34M | $30M | |
| Goodwill | $318M | $318M | $462M | $410M | $410M | · | · | · | · | · | · | · | |
| Intangibles | $15M | $390M | $457M | $410M | $411M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $9M | $9M | $13M | $11M | $1M | $43.0K | $42.0K | $43.0K | $45.0K | $10M | $8M | $29.0K | |
| Total Assets | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Accounts Payable | $21M | $17M | $15M | $12M | $11M | $4M | $8M | $7M | $9M | $8M | $5M | $6M | |
| Accrued Liabilities | $34M | $23M | $46M | $33M | $36M | $17M | $13M | $13M | $13M | $17M | $16M | $11M | |
| Short-term Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Current Liabilities | $73M | $66M | $95M | $263M | $72M | $39M | $49M | $27M | $29M | $34M | $38M | $31M | |
| Capital Leases | $57M | $15M | $32M | $41M | $50M | $38M | $42M | · | · | · | · | $2M | |
| Other Non-current Liabilities | $0 | $546.0K | $751.0K | $1M | $3M | $752.0K | · | · | · | $2M | $1M | $2M | |
| Total Liabilities | $779M | $754M | $1.04B | $1.20B | $1.22B | $78M | $93M | $56M | $58M | $53M | $58M | $69M | |
| Long-term Debt | · | · | · | $897M | $896M | · | $16M | $15M | $14M | $16M | · | $14M | |
| Total Debt | · | $0 | $490.0K | $2M | $2M | · | $16M | · | · | · | · | · | |
| Common Stock | $302.0K | $294.0K | $268.0K | $227.0K | $221.0K | $192.0K | $153.0K | $150.0K | $116.0K | $93.0K | $80.0K | $74.0K | |
| Paid-in Capital | $2.70B | $2.65B | $2.54B | $2.10B | $2.01B | $1.37B | $1.12B | $1.10B | $966M | $872M | $787M | $736M | |
| Retained Earnings | $-2.70B | $-2.15B | $-1.84B | $-1.53B | $-1.22B | $-1.04B | $-1.07B | $-982M | $-880M | $-788M | $-713M | $-681M | |
| AOCI | $457.0K | $422.0K | $219.0K | $-5M | $-1M | $85.0K | $5.0K | $-36.0K | $-32.0K | $5.0K | $-7.0K | $9.0K | |
| Stockholders' Equity | $5M | $507M | $701M | $563M | $791M | $335M | $55M | $114M | $86M | $85M | $74M | $55M | |
| Liabilities + Equity | $784M | $1.26B | $1.75B | $1.77B | $2.01B | $414M | $148M | $170M | $144M | $138M | $131M | $124M | |
| Shares Outstanding | 301,956,000 | 294,418,000 | 267,744,000 | 226,505,000 | 220,978,000 | 192,294,000 | 153,119,000 | 150,244,000 | 116,277,000 | 92,677,000 | 79,983,000 | 73,927,000 |
التدفق النقدي 16
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $7M | $8M | $4M | $4M | $4M | |
| Stock-based Comp | $42M | $71M | $72M | $79M | $73M | $18M | $16M | $23M | $20M | $20M | $14M | $10M | |
| Deferred Tax | $-546.0K | $-205.0K | $-11M | $0 | $-94M | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $369M | $27M | $8M | $913.0K | $0 | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $13M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | $6M | $-4M | $-17M | $-34M | $528.0K | |
| Operating Cash Flow | $-111M | $-206M | $-259M | $-263M | $-111M | $20M | $-78M | $-66M | $-68M | $-68M | $-48M | $-51M | |
| CapEx | $3M | $6M | $9M | $17M | $6M | $1M | $3M | $2M | $10M | $8M | $3M | $2M | |
| Investing Cash Flow | $115M | $124M | $5M | $116M | $-679M | $-219M | $62M | $-38M | $-2M | $-15M | · | · | |
| Stock Issued | $0 | $0 | $189M | $0 | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Net Stock Activity | $0 | $0 | $15M | $11M | $32M | $46M | $9M | $10M | $9M | $8M | $7M | $4M | |
| Financing Cash Flow | $3M | $-43M | $109M | $10M | $1.17B | $252M | $27M | $107M | $69M | $66M | · | · | |
| Net Change in Cash | $8M | $-125M | $-146M | $-138M | $380M | · | · | · | $-258.0K | $-17M | $-3M | $10M | |
| Taxes Paid | $481.0K | $256.0K | $140.0K | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-114M | $-212M | $-268M | $-280M | $-117M | $18M | $-81M | $-68M | $-78M | $-76M | $-51M | $-53M | |
| Levered FCF | · | · | $-282M | · | $-125M | · | · | · | · | · | · | · |
الربحية 8
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% | 31.9% | 37.1% | 48.7% | 57.6% | 38.6% | |
| Operating Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -128.4% | -96.1% | -78.5% | -31.4% | -103.7% | |
| Net Margin | -341.5% | -201.2% | -153.0% | -244.9% | -138.8% | 37.3% | -92.6% | -130.4% | -98.6% | -82.0% | -34.2% | -109.2% | |
| Pretax Margin | -341.3% | -201.0% | -158.7% | -244.9% | -210.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% | -132.3% | -110.6% | -119.3% | -87.0% | -74.3% | -27.4% | -96.8% | |
| ROA | -53.4% | -20.6% | -17.5% | -16.7% | -15.0% | 10.5% | -52.9% | -65.2% | -65.4% | -55.3% | -24.8% | -50.7% | |
| ROE | -1634.9% | -64.6% | -41.9% | -52.8% | -22.2% | 12.7% | -158.8% | -83.4% | -108.0% | -94.0% | -49.3% | -106.6% | |
| ROIC | -10360.5% | -93.7% | -46.0% | · | -17.5% | · | · | · | · | · | · | · |
السيولة والملاءة 4
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 | 9.2 | 1.6 | 4.9 | 3.5 | 3.2 | 2.9 | 3.7 | |
| Quick Ratio | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 | 8.7 | 1.3 | 4.1 | 2.7 | 2.5 | 2.3 | 3.3 | |
| Debt / Equity | · | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.3 | · | · | · | · | · | |
| Interest Coverage | · | · | -23.3 | -20.9 | -16.8 | -391.0 | -38.5 | -41.7 | -30.7 | -22.0 | -10.0 | -22.2 |
الكفاءة 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.6 | 0.5 | 0.7 | 0.7 | 0.7 | 0.5 | |
| Inventory Turnover | 2.1 | 2.0 | 2.8 | 2.1 | 3.7 | 3.4 | 3.6 | 2.6 | 3.0 | 3.5 | 3.5 | 3.5 | |
| Receivables Turnover | 5.1 | 4.8 | 7.2 | 6.0 | 6.4 | 4.9 | 7.6 | 7.1 | 7.5 | 10.9 | 21.4 | 19.7 |
معدلات النمو 3
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.9% | -23.2% | 56.3% | -1.7% | 65.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.6% | 5.7% | 36.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.2% | · | · | · | · | · | · | · | · | · | · | · |
التقييم (آخر 12 شهرًا) 14
| المقياس | اتجاه | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $160M | $154M | $201M | $128M | $131M | $79M | $91M | $79M | $93M | $91M | $93M | $61M | |
| Net Income TTM | $-546M | $-310M | $-307M | $-314M | $-181M | $29M | $-84M | $-103M | $-92M | $-74M | $-32M | $-66M | |
| Market Cap | $565M | $539M | $2.63B | $1.85B | $4.52B | $4.99B | $787M | $1.11B | $307M | $352M | $1.05B | $580M | |
| Enterprise Value | · | $149M | $2.00B | $1.08B | $3.48B | · | $754M | · | · | · | · | · | |
| P/E | -1.0 | -1.2 | -8.1 | -5.8 | -23.0 | 152.6 | -9.3 | -9.7 | · | · | · | · | |
| P/S | 3.5 | 3.5 | 13.1 | 14.4 | 34.6 | 63.2 | 8.7 | 14.1 | 3.3 | 3.9 | 11.3 | 9.6 | |
| P/B | 105.6 | 1.1 | 3.7 | 3.3 | 5.7 | 14.9 | 14.3 | 9.7 | 3.6 | 4.2 | 14.3 | 10.5 | |
| P / Tangible Book | · | · | · | · | · | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -2.6 | -10.1 | -7.0 | -40.7 | 255.8 | -10.0 | -16.7 | -4.5 | -5.2 | -21.9 | -11.3 | |
| P / FCF | -5.0 | -2.5 | -9.8 | -6.6 | -38.6 | 270.2 | -9.7 | -16.3 | -3.9 | -4.6 | -20.6 | -10.9 | |
| EV / EBITDA | · | -0.3 | -6.0 | -3.5 | -16.5 | · | -7.5 | · | · | · | · | · | |
| EV / FCF | · | -0.7 | -7.4 | -3.9 | -29.7 | · | -9.3 | · | · | · | · | · | |
| EV / Revenue | · | 1.0 | 10.0 | 8.4 | 26.7 | · | 8.3 | · | · | · | · | · | |
| Earnings Yield | -97.3% | -86.9% | -12.3% | -17.1% | -4.3% | 0.66% | -10.7% | -10.3% | · | · | · | · |
قائمة الدخل 17
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39M | $37M | $45M | $38M | $40M | $37M | $39M | $40M | $36M | $39M | $58M | $56M | $48M | $39M | $27M | $32M | |
| Cost of Revenue | $26M | $24M | $28M | $23M | $25M | $39M | $29M | $30M | $30M | $28M | $49M | $38M | $32M | $29M | $22M | $19M | |
| Gross Profit | $13M | $13M | $17M | $16M | $15M | $-1M | $10M | $10M | $6M | $11M | $10M | $18M | $16M | $10M | $5M | $14M | |
| R&D Expense | $23M | $20M | $23M | $23M | $23M | $29M | $27M | $26M | $38M | $43M | $45M | $48M | $46M | $49M | $43M | $47M | |
| SG&A Expense | $33M | $31M | $34M | $31M | $36M | $40M | $42M | $44M | $46M | $44M | $46M | $43M | $41M | $40M | $45M | $37M | |
| Operating Expenses | $57M | $21M | $58M | $55M | $60M | $428M | $163M | $74M | $182M | $93M | $97M | $100M | $89M | $101M | $92M | $88M | |
| Operating Income | $-45M | $-8M | $-41M | $-39M | $-45M | $-429M | $-153M | $-64M | $-176M | $-81M | $-88M | $-82M | $-73M | $-91M | $-87M | $-75M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $4M | · | $4M | $4M | $4M | · | $4M | |
| Other Non-op | $2M | $2M | $3M | $3M | $5M | $4M | $4M | $7M | $6M | $7M | $8M | $9M | $9M | $7M | $6M | $1M | |
| Pretax Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $3M | $-61M | $-173M | $-78M | $-83M | $-78M | $-70M | $-88M | $-84M | $-77M | |
| Income Tax | $58.0K | $184.0K | $202.0K | $383.0K | $35.0K | $-302.0K | $316.0K | $0 | $0 | $0 | $-718.0K | $-11M | $0 | $0 | $0 | $0 | |
| Net Income | $-45M | $-8M | $-40M | $-38M | $-42M | $-426M | $2M | $-61M | $-173M | $-78M | $-82M | $-67M | $-70M | $-88M | $-84M | $-77M | |
| EPS (Basic) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $0.02 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| EPS (Diluted) | $-0.14 | $-0.03 | $-0.11 | $-0.13 | $-0.14 | $-1.44 | $-0.44 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 | $-0.28 | $-0.36 | $-0.37 | $-0.34 | |
| Shares (Basic) | 310,655,000 | 305,819,000 | -597,905,000 | 300,844,000 | 300,162,000 | 296,858,000 | -540,390,000 | 272,915,000 | 272,385,000 | 269,578,000 | -493,474,000 | 255,001,000 | 250,070,000 | 242,032,000 | -447,361,000 | 225,123,000 | |
| Shares (Diluted) | 310,655,000 | 305,819,000 | -597,905,000 | 300,844,000 | 300,162,000 | 296,858,000 | -526,512,000 | 272,915,000 | 272,385,000 | 269,578,000 | -493,474,000 | 255,001,000 | 250,070,000 | 242,032,000 | -447,361,000 | 225,123,000 | |
| EBITDA | $-45M | $-8M | · | $-39M | $-45M | $-429M | · | $-64M | $-176M | $-81M | · | $-82M | $-73M | $-91M | · | $-75M |
الميزانية العمومية 27
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61M | $56M | $64M | $56M | $55M | $59M | $55M | $78M | $100M | $77M | $180M | $386M | $209M | $354M | $325M | $304M | |
| Short-term Investments | $176M | $220M | $216M | $242M | $260M | $285M | $335M | $393M | $410M | $485M | · | $382M | $621M | $521M | · | $530M | |
| Receivables | $31M | $29M | $35M | $31M | $32M | $32M | $28M | $29M | $32M | $30M | · | $30M | $24M | $30M | · | $23M | |
| Inventory | $61M | $51M | $49M | $53M | $54M | $54M | $59M | $66M | $69M | $67M | · | $68M | $68M | $62M | · | $43M | |
| Prepaid Expense | $10M | $13M | $11M | $12M | $12M | $15M | $19M | $17M | $17M | $17M | · | $15M | $14M | $14M | · | $13M | |
| Current Assets | $339M | $370M | $375M | $394M | $413M | $445M | $496M | $584M | $628M | $677M | · | $882M | $936M | $981M | · | $914M | |
| PP&E (Net) | $27M | $24M | $24M | $22M | $23M | $25M | $31M | $32M | $35M | $37M | · | $40M | $40M | $41M | · | $39M | |
| PP&E (Gross) | · | · | $117M | · | · | · | $112M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $92M | · | · | · | $82M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $318M | $318M | $318M | $318M | $318M | $318M | $318M | $369M | $369M | $462M | · | $464M | $410M | $410M | · | $410M | |
| Intangibles | $13M | $14M | $15M | $16M | $17M | $18M | $390M | $436M | $443M | $450M | · | $462M | $410M | $410M | · | $410M | |
| Other Non-current Assets | $13M | $14M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $10M | · | $13M | $13M | $13M | · | $1M | |
| Total Assets | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Accounts Payable | $19M | $14M | $21M | $16M | $15M | $14M | $17M | $12M | $17M | $21M | · | $16M | $17M | $17M | · | $13M | |
| Accrued Liabilities | $30M | $34M | $34M | $29M | $27M | $29M | $23M | $19M | $22M | $22M | · | $35M | $27M | $19M | · | $25M | |
| Current Liabilities | $69M | $65M | $73M | $63M | $60M | $67M | $66M | $60M | $78M | $73M | · | $184M | $271M | $266M | · | $82M | |
| Capital Leases | $60M | $59M | $57M | $54M | $52M | $50M | $15M | $17M | $20M | $29M | · | $34M | $37M | $39M | · | $43M | |
| Other Non-current Liabilities | $8M | $8M | $0 | $0 | $0 | $0 | $546.0K | $751.0K | $751.0K | $751.0K | · | $1M | $837.0K | $969.0K | · | $2M | |
| Total Liabilities | $785M | $780M | $779M | $767M | $764M | $769M | $754M | $997M | $1.02B | $1.02B | · | $1.13B | $1.21B | $1.20B | · | $1.19B | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | · | · | · | $897M | · | $897M | |
| Common Stock | $311.0K | $311.0K | $302.0K | $302.0K | $300.0K | $300.0K | $294.0K | $274.0K | $272.0K | $272.0K | · | $258.0K | $250.0K | $250.0K | · | $226.0K | |
| Paid-in Capital | $2.72B | $2.71B | $2.70B | $2.69B | $2.68B | $2.67B | $2.65B | $2.60B | $2.58B | $2.57B | · | $2.52B | $2.33B | $2.31B | · | $2.08B | |
| Retained Earnings | $-2.75B | $-2.70B | $-2.70B | $-2.65B | $-2.62B | $-2.58B | $-2.15B | $-2.15B | $-2.09B | $-1.92B | · | $-1.76B | $-1.69B | $-1.62B | · | $-1.45B | |
| AOCI | $-503.0K | $-147.0K | $457.0K | $415.0K | $267.0K | $381.0K | $422.0K | $2M | $-523.0K | $-306.0K | · | $-2M | $-3M | $-2M | · | $-6M | |
| Stockholders' Equity | $-33M | $2M | $5M | $36M | $61M | $92M | $507M | $453M | $493M | $649M | $701M | $764M | $642M | $692M | $563M | $627M | |
| Liabilities + Equity | $752M | $782M | $784M | $803M | $825M | $861M | $1.26B | $1.45B | $1.51B | $1.67B | · | $1.90B | $1.85B | $1.90B | · | $1.82B | |
| Shares Outstanding | 310,810,000 | 310,487,000 | 301,956,000 | 301,853,000 | 300,350,000 | 300,041,000 | 294,418,000 | 273,812,000 | 272,491,000 | 272,280,000 | 267,744,000 | 258,374,000 | 250,473,000 | 249,803,000 | 226,505,000 | 225,916,000 |
التدفق النقدي 12
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $9M | $4M | $10M | $11M | $12M | $9M | $16M | $18M | $17M | $20M | $17M | $20M | $18M | $18M | $18M | $19M | |
| Amort. of Intangibles | · | $1M | $1M | $1M | $1M | $366M | $7M | $7M | $7M | $7M | $7M | $942.0K | $232.0K | $234.0K | $228.0K | $229.0K | |
| Restructuring | · | · | · | · | · | · | · | · | $11M | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-36M | $-45M | $-19M | $-19M | $-29M | $-44M | $-31M | $-45M | $-54M | $-76M | $-58M | $-65M | $-42M | $-95M | $-61M | $-63M | |
| CapEx | $2M | $3M | $861.0K | $-86.0K | $550.0K | $1M | $2M | $-787.0K | $1M | $4M | $2M | $830.0K | $2M | $4M | $5M | $4M | |
| Investing Cash Flow | $40M | $36M | $26M | $19M | $25M | $45M | $58M | $23M | $77M | $-34M | $-67M | $242M | $-99M | $-73M | $80M | $54M | |
| Stock Issued | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $189M | $0 | $-6M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $189M | · | · | |
| Financing Cash Flow | $255.0K | $1M | $0 | $1M | $0 | $2M | $-50M | $812.0K | $-152.0K | $7M | $-82M | $-781.0K | $-5M | $196M | $819.0K | $3M | |
| Net Change in Cash | $5M | $-7M | $7M | $2M | $-4M | $3M | $-23M | $-22M | $22M | $-103M | $-206M | $176M | $-145M | $29M | $21M | $-6M | |
| Free Cash Flow | · | $-48M | · | · | · | $-45M | · | · | · | $-80M | · | · | · | $-98M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-83M | · | · | · | $-102M | · | · |
الربحية 8
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4% | 34.5% | · | 41.4% | 36.9% | -3.7% | · | 25.0% | 16.5% | 29.1% | · | 32.1% | 32.7% | 25.1% | · | 41.9% | |
| Operating Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| Net Margin | -114.7% | -22.3% | · | -98.9% | -105.4% | -1146.8% | · | -151.9% | -481.3% | -201.4% | · | -120.1% | -146.8% | -226.3% | · | -238.2% | |
| Pretax Margin | -114.5% | -21.8% | · | -97.9% | -105.4% | -1147.6% | · | -151.9% | -481.3% | -201.4% | · | -139.3% | -146.8% | -226.3% | · | -238.2% | |
| EBITDA Margin | -114.4% | -22.5% | · | -101.1% | -112.8% | -1154.5% | · | -160.3% | -488.3% | -209.6% | · | -148.1% | -153.8% | -234.6% | · | -230.9% | |
| ROA | -5.7% | -1.0% | · | -3.4% | -3.6% | -33.7% | · | -3.6% | -10.3% | -4.4% | · | -3.6% | -3.8% | -4.6% | · | -4.0% | |
| ROE | -316.5% | -17.6% | · | -15.5% | -15.1% | -115.1% | · | -10.0% | -30.6% | -11.7% | · | -9.6% | -10.5% | -12.3% | · | -10.5% | |
| ROIC | 134.5% | -361.2% | · | -108.8% | -73.0% | -467.7% | · | -14.1% | -35.7% | -12.5% | · | -9.3% | -11.4% | -13.2% | · | · |
السيولة والملاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.7 | · | 6.2 | 6.9 | 6.7 | · | 9.7 | 8.0 | 9.3 | · | 4.8 | 3.4 | 3.7 | · | 11.2 | |
| Quick Ratio | 3.9 | 4.7 | · | 5.2 | 5.8 | 5.6 | · | 8.3 | 6.9 | 8.1 | · | 4.3 | 3.1 | 3.4 | · | 10.5 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -22.8 | · | -23.0 | -20.6 | -25.1 | · | -20.4 |
الكفاءة 3
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.4 | 0.6 | · | 0.4 | 0.4 | 0.4 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.3 | 1.2 | 1.2 | · | 1.3 | 1.3 | 1.3 | · | 2.1 | 1.9 | 1.4 | · | 1.4 |
التقييم (آخر 12 شهرًا) 9
| المقياس | اتجاه | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $154M | $153M | · | $155M | $153M | $152M | · | $170M | $178M | $181M | · | $174M | $154M | $140M | · | $136M | |
| Net Income TTM | $-133M | $-514M | · | $-567M | $-702M | $-738M | · | $-379M | $-388M | $-303M | · | $-302M | $-306M | $-318M | · | $-213M | |
| Market Cap | $522M | $410M | · | $386M | $372M | $354M | · | $465M | $373M | $1.02B | · | $2.16B | $3.33B | $2.89B | · | $1.31B | |
| P/E | -3.8 | -0.8 | · | -0.7 | -0.5 | -0.5 | · | -1.2 | -0.9 | -3.2 | · | -6.7 | -10.2 | -8.3 | · | -6.1 | |
| P/S | 3.4 | 2.7 | · | 2.5 | 2.4 | 2.3 | · | 2.7 | 2.1 | 5.6 | · | 12.4 | 21.6 | 20.7 | · | 9.7 | |
| P/B | -15.7 | 173.2 | · | 10.7 | 6.1 | 3.9 | · | 1.0 | 0.8 | 1.6 | · | 2.8 | 5.2 | 4.2 | · | 2.1 | |
| P / Cash Flow | · | -9.2 | · | · | · | -8.0 | · | · | · | -13.5 | · | · | · | -30.5 | · | · | |
| P / FCF | · | -8.6 | · | · | · | -7.8 | · | · | · | -12.8 | · | · | · | -29.4 | · | · | |
| Earnings Yield | -26.2% | -131.8% | · | -150.8% | -196.8% | -219.5% | · | -82.9% | -107.3% | -31.7% | · | -14.8% | -9.8% | -12.0% | · | -16.4% |
القوائم المالية قائمة الدخل، الميزانية العمومية، التدفقات النقدية — سنويًا، آخر 5 سنوات
قائمة الدخل
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الإيرادات | $160M | $154M | $201M | $128M | $131M |
| هامش الربح الإجمالي % | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% |
| هامش الربح التشغيلي % | -346.1% | -308.0% | -166.8% | -239.4% | -161.2% |
| صافي الدخل | $-546M | $-310M | $-307M | $-314M | $-181M |
| EPS المخفف | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
الميزانية العمومية
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| الدين / حقوق الملكية | — | 0.0 | 0.0 | 0.0 | 0.0 |
| النسبة الحالية | 5.1 | 7.5 | 7.8 | 3.2 | 15.4 |
| النسبة السريعة | 4.3 | 6.3 | 7.0 | 3.0 | 14.9 |
التدفق النقدي
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| التدفق النقدي الحر | $-114M | $-212M | $-268M | $-280M | $-117M |
مقاييسي قائمة المراقبة الشخصية الخاصة بك — صفوف مختارة من الأساسيات الكاملة
📊
اختر المقاييس التي تهمك — انقر فوق علامة ➕ بجوار أي صف في الأساسيات الكاملة أعلاه.
يتم حفظ اختيارك ويتبعك عبر جميع الأسهم.
الملاك المؤسسيون (13F) 247 مقدمي إقرار · $274.5M إجمالي · حتى تاريخ 30 يونيو، 2026
المؤسسات التي تبلغ عن حيازتها لهذا السهم في نموذج SEC 13F ربع السنوي الخاص بها. المراكز الطويلة فقط؛ قد يظهر مقدم واحد مرتين لأرجل خيارات منفصلة. الأرجل الكبيرة المتعاكسة من خيارات البيع/الشراء تعكس عادةً صناعة السوق أو المخزون المتحوط، وليس القناعة الاتجاهية.
النشاط المؤسسي — Q2 2026 مقابل الربع السابق
| مراكز جديدة | المراكز الخارجة | زيادة | انخفض | صافي التغير في الأسهم |
|---|---|---|---|---|
| 29 (-25 مقابل الربع السابق) | 28 (-2 مقابل الربع السابق) | 65 (+10 مقابل الربع السابق) | 79 (+2 مقابل الربع السابق) | -4.8M |
مقارنة بـ Q1 2026. المواعيد النهائية لتقديم إقرارات نموذج 13F لهيئة الأوراق المالية والبورصات (SEC) هي في غضون 45 يومًا من نهاية الربع بالإضافة إلى فترة سماح قصيرة للمقدمين المتأخرين — يتم تخطي الأرباع التي لا تزال ضمن هذه النافذة لصالح أحدث زوج تم الإبلاغ عنه بالكامل.
| مؤسسة | القيمة | الأسهم | % من 13F المتتبعة | النوع |
|---|---|---|---|---|
| ARK Investment Management LLC | $50032778 | 29781416 | 18,23% | الأسهم |
| SOFTBANK GROUP CORP. | $34358638 | 20451570 | 12,52% | الأسهم |
| VANGUARD GROUP INC | $28083542 | 15017937 | 10,23% | الأسهم |
| VANGUARD CAPITAL MANAGEMENT LLC | $22508529 | 13397934 | 8,20% | الأسهم |
| GEODE CAPITAL MANAGEMENT, LLC | $10951905 | 6516920 | 3,99% | الأسهم |
| Sumitomo Mitsui Trust Group, Inc. | $10096321 | 6009715 | 3,68% | الأسهم |
| Amova Asset Management Americas, Inc. | $10036224 | 6009715 | 3,66% | الأسهم |
| STATE STREET CORP | $10014774 | 5961175 | 3,65% | الأسهم |
| Point72 Asset Management, L.P. | $8042664 | 4787300 | 2,93% | الأسهم |
| TWO SIGMA INVESTMENTS, LP | $7127566 | 4242599 | 2,60% | الأسهم |
| MILLENNIUM MANAGEMENT LLC | $6656903 | 3962442 | 2,43% | الأسهم |
| Point72 (DIFC) Ltd | $5465775 | 4270137 | 1,99% | الأسهم |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4488819 | 2671916 | 1,64% | الأسهم |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4455861 | 2652298 | 1,62% | الأسهم |
| D. E. Shaw & Co., Inc. | $3959804 | 2357026 | 1,44% | الأسهم |
| VANGUARD FIDUCIARY TRUST CO | $3675213 | 2187627 | 1,34% | الأسهم |
| Longaeva Partners L.P. | $3558628 | 2118231 | 1,30% | الأسهم |
| GOLDMAN SACHS GROUP INC | $3262914 | 1942211 | 1,19% | الأسهم |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $2846837 | 1694546 | 1,04% | الأسهم |
| Birchview Capital, LP | $2268000 | 1350000 | 0,83% | الأسهم |
| BlackRock, Inc. | $2210561 | 1315810 | 0,81% | الأسهم |
| BANK OF AMERICA CORP /DE/ | $1812811 | 1079054 | 0,66% | الأسهم |
| RENAISSANCE TECHNOLOGIES LLC | $1623216 | 966200 | 0,59% | الأسهم |
| BOURNE LENT ASSET MANAGEMENT INC | $1584332 | 943055 | 0,58% | الأسهم |
| TWO SIGMA ADVISERS, LP | $1547425 | 827500 | 0,56% | الأسهم |
| HHLR ADVISORS, LTD. | $1543739 | 918892 | 0,56% | الأسهم |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $1358616 | 808700 | 0,49% | الأسهم |
| Casdin Capital, LLC | $1215929 | 723767 | 0,44% | الأسهم |
| TUDOR INVESTMENT CORP ET AL | $1150308 | 684707 | 0,42% | الأسهم |
| DIMENSIONAL FUND ADVISORS LP | $1095649 | 652172 | 0,40% | الأسهم |
| XTX Topco Ltd | $1073322 | 638882 | 0,39% | الأسهم |
| Numerai GP LLC | $1044068 | 621469 | 0,38% | الأسهم |
| CARRET ASSET MANAGEMENT, LLC | $1008235 | 600140 | 0,37% | الأسهم |
| Man Group plc | $1003521 | 597334 | 0,37% | الأسهم |
| Balyasny Asset Management L.P. | $948090 | 564339 | 0,35% | الأسهم |
| PEAK6 LLC | $933327 | 555552 | 0,34% | الأسهم |
| Vestmark Advisory Solutions, Inc. | $803384 | 478205 | 0,29% | الأسهم |
| ArrowMark Colorado Holdings LLC | $786882 | 468382 | 0,29% | الأسهم |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $741954 | 441639 | 0,27% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $673008 | 400600 | 0,25% | عقد خيار البيع |
| RHUMBLINE ADVISERS | $599738 | 356996 | 0,22% | الأسهم |
| CAXTON ASSOCIATES LP | $577087 | 315348 | 0,21% | الأسهم |
| Mirador Capital Partners LP | $575370 | 342482 | 0,21% | الأسهم |
| LPL Financial LLC | $567003 | 337502 | 0,21% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $566071 | 336947 | 0,21% | الأسهم |
| Connor, Clark & Lunn Investment Management Ltd. | $529407 | 315123 | 0,19% | الأسهم |
| ALLIANCEBERNSTEIN L.P. | $510919 | 387060 | 0,19% | الأسهم |
| Qube Research & Technologies Ltd | $500558 | 297951 | 0,18% | الأسهم |
| Nuveen Asset Management, LLC | $494437 | 270184 | 0,18% | الأسهم |
| GROUP ONE TRADING LLC | $488645 | 290860 | 0,18% | الأسهم |
| WATER ISLAND CAPITAL LLC | $459759 | 273666 | 0,17% | الأسهم |
| HSBC HOLDINGS PLC | $457555 | 277306 | 0,17% | الأسهم |
| BARCLAYS PLC | $447482 | 266359 | 0,16% | الأسهم |
| WELLS FARGO & COMPANY/MN | $430196 | 256069 | 0,16% | الأسهم |
| Bank of New York Mellon Corp | $426179 | 253678 | 0,16% | الأسهم |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $406056 | 241700 | 0,15% | عقد خيار الشراء |
| Quadrature Capital Ltd | $311899 | 185654 | 0,11% | الأسهم |
| Green Alpha Advisors, LLC | $300140 | 178655 | 0,11% | الأسهم |
| MARSHALL WACE, LLP | $274919 | 163642 | 0,10% | الأسهم |
| UBS Group AG | $271868 | 161826 | 0,10% | الأسهم |
| MetLife Investment Management, LLC | $264093 | 157198 | 0,10% | الأسهم |
| RAYMOND JAMES FINANCIAL INC | $260524 | 155074 | 0,09% | الأسهم |
| AdvisorNet Financial, Inc | $255565 | 152122 | 0,09% | الأسهم |
| Main Street Research LLC | $255528 | 152100 | 0,09% | الأسهم |
| JANE STREET GROUP, LLC | $255192 | 151900 | 0,09% | عقد خيار الشراء |
| Voleon Capital Management LP | $226521 | 134834 | 0,08% | الأسهم |
| ENVESTNET ASSET MANAGEMENT INC | $223315 | 132926 | 0,08% | الأسهم |
| IEQ CAPITAL, LLC | $207954 | 123782 | 0,08% | الأسهم |
| CITIGROUP INC | $206867 | 123135 | 0,08% | الأسهم |
| Vanguard Global Advisers, LLC | $204592 | 121781 | 0,07% | الأسهم |
| Koa Wealth Management, LLC | $201600 | 120000 | 0,07% | الأسهم |
| Invesco Ltd. | $188456 | 112176 | 0,07% | الأسهم |
| CITADEL ADVISORS LLC | $186144 | 110800 | 0,07% | عقد خيار الشراء |
| BENJAMIN EDWARDS INC | $179922 | 107153 | 0,07% | الأسهم |
| KAVAR CAPITAL PARTNERS GROUP, LLC | $173576 | 103319 | 0,06% | الأسهم |
| Bridgewater Associates, LP | $172638 | 102761 | 0,06% | الأسهم |
| GABELLI FUNDS LLC | $168000 | 100000 | 0,06% | الأسهم |
| CITADEL ADVISORS LLC | $152964 | 91050 | 0,06% | الأسهم |
| NEW YORK STATE COMMON RETIREMENT FUND | $142506 | 84825 | 0,05% | الأسهم |
| Police & Firemen's Retirement System of New Jersey | $134324 | 79955 | 0,05% | الأسهم |
| NJ State Employees Deferred Compensation Plan | $128000 | 100000 | 0,05% | الأسهم |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $126573 | 75341 | 0,05% | الأسهم |
| HUB Investment Partners, LLC | $126000 | 75000 | 0,05% | الأسهم |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $120861 | 71941 | 0,04% | الأسهم |
| HARTLINE INVESTMENT CORP/ | $115920 | 69000 | 0,04% | الأسهم |
| Cerity Partners LLC | $115811 | 68935 | 0,04% | الأسهم |
| STIFEL FINANCIAL CORP | $114659 | 68249 | 0,04% | الأسهم |
| INTECH INVESTMENT MANAGEMENT LLC | $113249 | 67410 | 0,04% | الأسهم |
| SIMPLEX TRADING, LLC | $110307 | 65659 | 0,04% | الأسهم |
| CITADEL ADVISORS LLC | $109536 | 65200 | 0,04% | عقد خيار البيع |
| Nuveen, LLC | $99117 | 58998 | 0,04% | الأسهم |
| VOYA INVESTMENT MANAGEMENT LLC | $96004 | 57145 | 0,03% | الأسهم |
| CAPTRUST FINANCIAL ADVISORS | $94854 | 56461 | 0,03% | الأسهم |
| Cetera Investment Advisers | $91834 | 54663 | 0,03% | الأسهم |
| State of Wyoming | $91169 | 54267 | 0,03% | الأسهم |
| MERCER GLOBAL ADVISORS INC /ADV | $86972 | 51769 | 0,03% | الأسهم |
| Abacus Planning Group, Inc. | $86080 | 51238 | 0,03% | الأسهم |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | $85770 | 54981 | 0,03% | الأسهم |
| Evolution Wealth Advisors, LLC | $84000 | 50000 | 0,03% | الأسهم |
| China Universal Asset Management Co., Ltd. | $83046 | 49432 | 0,03% | الأسهم |
المطلعون على الشركة 30 من المطلعين · مسؤولون 6 · مديرون 11
| مطلع | الدور | آخر نشاط | الأسهم المملوكة | مشتريات 12 شهرًا | مبيعات 12 شهرًا | صافي 12 شهرًا |
|---|---|---|---|---|---|---|
| Mark Van Oene | President & CEO | 17 أغسطس، 2026 S | 2705853 | 0 | 5 | $-370277 |
| Susan K Barnes | EVP, CFO and PAO | 19 فبراير، 2020 S | 874812 | 0 | 0 | $0 |
| James Michael Phillips | SVP, Research & Development | 24 مارس، 2020 S | 249220 | 0 | 0 | $0 |
| Kevin P Corcoran | SVP, Market Development | 24 نوفمبر، 2017 M | 158174 | 0 | 0 | $0 |
| Michael Glynn | Chief Commercial Officer | 15 فبراير، 2012 A | — | 0 | 0 | $0 |
| Stephen W Turner | VP & Chief Technology Officer | 11 يوليو، 2011 J | 1093063 | 0 | 0 | $0 |
| Christopher Gibson | مدير | 3 يونيو، 2026 A | 53913 | 0 | 0 | $0 |
| Hannah Valantine | مدير | 3 يونيو، 2026 A | 22821 | 0 | 0 | $0 |
| William W. Ericson | مدير | 3 يونيو، 2026 A | 41616 | 0 | 0 | $0 |
| Christopher M Smith | مدير | 3 يونيو، 2026 A | 54099 | 0 | 0 | $0 |
| Marshall Mohr | مدير | 3 يونيو، 2026 A | 132821 | 0 | 0 | $0 |
| Randall S Livingston | مدير | 3 يونيو، 2026 A | 22821 | 0 | 0 | $0 |
| Kathy Ordonez | مدير | 3 يونيو، 2026 A | 403037 | 0 | 0 | $0 |
| John F Milligan | مدير | 3 يونيو، 2026 A | 132821 | 0 | 0 | $0 |
| David B. Singer | مدير | 13 يونيو، 2012 A | — | 0 | 0 | $0 |
| Susan E Siegel | مدير | 13 يونيو، 2012 A | 65000 | 0 | 0 | $0 |
| Hugh C Martin | مدير | 3 فبراير، 2012 M | 342458 | 0 | 0 | $0 |
| James R Gibson II | — | 1 إبريل، 2026 S | 1245663 | 0 | 1 | $-120813 |
| Michele Farmer | — | 3 مارس، 2026 S | 305948 | 0 | 3 | $-84510 |
| Christian O Henry | — | 3 مارس، 2026 S | 3581813 | 0 | 3 | $-772728 |
| Lucy Shapiro | — | 4 يونيو، 2025 A | 22821 | 0 | 0 | $0 |
| Susan G. Kim | — | 30 سبتمبر، 2024 S | 695654 | 0 | 0 | $0 |
| Jeff Eidel | — | 19 أغسطس، 2024 S | 869730 | 0 | 0 | $0 |
| David W Meline | — | 18 يونيو، 2024 A | 57116 | 0 | 0 | $0 |
| David Botstein | — | 24 مايو، 2023 A | 0 | 0 | 0 | $0 |
| Peter Fromen | — | 2 مارس، 2022 A | 190280 | 0 | 0 | $0 |
| Michael Hunkapiller | — | 26 فبراير، 2021 M | 848405 | 0 | 0 | $0 |
| Eric Schaefer | — | 22 فبراير، 2021 S | 88474 | 0 | 0 | $0 |
| BYERS BROOK H | — | 17 مايو، 2016 A | 110504 | 0 | 0 | $0 |
| Brian B Dow | — | 2 مارس، 2015 P | 18119 | 0 | 0 | $0 |
المطلعون من إيداعات SEC Form 3/4/5؛ صافي = سوق مفتوح فقط
الناشطون والمالكون بنسبة 5%+ 1 حيازة
المستثمرون الذين قدموا الجدول الزمني 13D لدى هيئة الأوراق المالية والبورصات — ملكية مستفيدة تزيد عن 5% مع نية التأثير على المُصدر (حصص الناشطين، حملات مجلس الإدارة، الاندماج والاستحواذ). يعرض كل صف أحدث حالة معروفة لمركز مقدم الطلب هذا.
| مقدم | مقدم | حصة | الحالة | الغرض | إيداع |
|---|---|---|---|---|---|
| Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC, Alec N. Litowitz ×3 إيداعات | 29 أغسطس، 2019 | — | إيداع أولي | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ملكية صناديق المؤشرات المتداولة محتفظ بها بواسطة 32 صناديق مؤشرات متداولة
الوزن يعكس فقط ممتلكات الأسهم المباشرة (N-PORT)؛ قد تحتفظ الصناديق المضاعفة أو القائمة على المشتقات بتعرض إضافي للمقايضة غير معروض.
| صندوق | الوزن | الوحدات | حتى تاريخ | المصدر |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 1,41% | 10964895 NS | 30 إبريل، 2026 | N-PORT |
| EVNT · AltShares Trust | 0,75% | 62040 NS | 31 مايو، 2026 | N-PORT |
| GNOM · Global X Funds | 0,40% | 151435 NS | 31 مايو، 2026 | N-PORT |
| ARKK · ARK ETF Trust | 0,36% | 14733201 NS | 30 إبريل، 2026 | N-PORT |
| BIB · ProShares Trust | 0,02% | 11163 NS | 31 مايو، 2026 | N-PORT |
| RSSL · Global X Funds | 0,01% | 121533 NS | 30 إبريل، 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 12995 NS | 31 مايو، 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 1434895 NS | 31 مايو، 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 10163 NS | 31 مايو، 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 10278 NS | 31 مايو، 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 9612 NS | 31 مايو، 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 258 NS | 31 مايو، 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 174278 NS | 31 مايو، 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 48231 NS | 30 إبريل، 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 8144 NS | 30 إبريل، 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 يوليو، 2026 | يومي |
| ITOT · iShares Trust | — | — | 22 يوليو، 2026 | يومي |
| IWV · iShares Trust | — | — | 18 أغسطس، 2026 | يومي |
| IWN · iShares Trust | — | — | 17 أغسطس، 2026 | يومي |
| IWO · iShares Trust | — | — | 18 أغسطس، 2026 | يومي |
| IWM · iShares Trust | — | — | 18 أغسطس، 2026 | يومي |
| IBB · iShares Trust | — | — | 18 أغسطس، 2026 | يومي |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 20 يوليو، 2026 | يومي |
| VHT · VANGUARD WORLD FUND | — | — | 20 يوليو، 2026 | يومي |
| IDNA · iShares Trust | — | — | 12 أغسطس، 2026 | يومي |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | 20 يوليو، 2026 | يومي |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 20 يوليو، 2026 | يومي |